You are here

  • Home
  • Archive
  • Volume 82, Issue 12
  • Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Citation Tools

Article menu
Rheumatoid arthritis
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Taylor PC, Weinblatt ME, McInnes IB, et al
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
Annals of the Rheumatic Diseases 2023;82:1527-1537.